426 related articles for article (PubMed ID: 18219303)
1. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy.
Cohn JN; Goldman JM
Am J Hypertens; 2008 Mar; 21(3):248-56. PubMed ID: 18219303
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
4. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
5. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
Bommer WJ
Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
[TBL] [Abstract][Full Text] [Related]
6. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
Ruilope LM
Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
[TBL] [Abstract][Full Text] [Related]
7. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.
Doulton TW; MacGregor GA
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):185-9. PubMed ID: 19617273
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
Böhm M
Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
[TBL] [Abstract][Full Text] [Related]
9. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Weber MA
Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
[TBL] [Abstract][Full Text] [Related]
10. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
[TBL] [Abstract][Full Text] [Related]
11. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
12. Are there effects of renin-angiotensin system antagonists beyond blood pressure control?
Bakris G
Am J Cardiol; 2010 Jan; 105(1 Suppl):21A-9A. PubMed ID: 20102970
[TBL] [Abstract][Full Text] [Related]
13. Dual blockade of the renin-angiotensin system for cardiorenal protection: an update.
Arici M; Erdem Y
Am J Kidney Dis; 2009 Feb; 53(2):332-45. PubMed ID: 19166800
[TBL] [Abstract][Full Text] [Related]
14. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
15. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
Toto R; Palmer BF
Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
17. Rationale for combining blockers of the renin-angiotensin system.
Azizi M; Wuerzner G
Semin Nephrol; 2007 Sep; 27(5):544-54. PubMed ID: 17868792
[TBL] [Abstract][Full Text] [Related]
18. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
[TBL] [Abstract][Full Text] [Related]
19. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
Catapano F; Chiodini P; De Nicola L; Minutolo R; Zamboli P; Gallo C; Conte G
Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
[TBL] [Abstract][Full Text] [Related]
20. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
Carson PE
Am Heart J; 2000 Sep; 140(3):361-6. PubMed ID: 10966531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]